In advanced heart failure patients treated with fully magnetically levitated left ventricular assist devices (LVADs), the exclusion of aspirin from antithrombotic therapy appears to be safe. A study found that aspirin exclusion did not increase the risk of adverse events related to stroke or bleeding in these patients. This suggests that using only an antiplatelet agent and an oral anticoagulant may be a safe and effective antithrombotic regimen for advanced heart failure patients with fully magnetically levitated LVADs. These findings may have implications for optimizing antithrombotic therapy in this patient population.
Source link
Aspirin Exclusion from antithrobotic regimen safe in advanced HF patients treated with fully magnetically levitated LVAD
